Inseego (INSG) Falls Short of Q3 Earnings Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy INSG?
Source: NASDAQ.COM
Earnings Performance: Inseego (INSG) reported quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.28, and showing a significant earnings surprise of -57.14%. The company also posted revenues of $45.89 million, exceeding estimates by 9.36%.
Stock Outlook: Despite the earnings miss, Inseego shares have increased by approximately 40.4% year-to-date, outperforming the S&P 500's 15.6% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Future Earnings Estimates: The consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $45.4 million, with a fiscal year estimate of $0.97 on $160.1 million in revenues. The outlook for the industry, particularly the Internet - Software sector, is currently favorable, ranking in the top 35% of Zacks industries.
Comparison with Peers: Another company in the same industry, Elastic (ESTC), is expected to report quarterly earnings of $0.58, reflecting a slight year-over-year decline. The consensus estimate for Elastic has been revised significantly higher, indicating positive sentiment in the sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSG
Wall Street analysts forecast INSG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSG is 16.60 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 9.850
Low
14.00
Averages
16.60
High
20.00
Current: 9.850
Low
14.00
Averages
16.60
High
20.00
About INSG
Inseego Corp. is engaged in the design and development of cloud-managed wireless wide area network (WAN) and intelligent edge solutions. Its 5G WAN portfolio comprises secure and high-performance mobile broadband and fixed wireless access (FWA) solutions with associated cloud solutions for real time WAN visibility, monitoring, automation and control with centralized orchestration of network functions. These devices are specifically built for the carrier, enterprise and small and medium business market segments. It also provides a wireless subscriber management SaaS solution for carrier’s management of their government and complex enterprise customer subscriptions. Its 4G and 5G devices connect end users with high-performance broadband for both mobile and fixed wireless use cases. Its 5G products and associated cloud solutions are used in applications, such as broadband for both mobile and fixed use cases, enterprise networking and software-defined wide area network failover management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inseego to Showcase 5G Solutions at MWC 2026
- Participation in MWC 2026: Inseego will showcase its 5G mobile broadband and fixed wireless access solutions at the Mobile World Congress in Barcelona from March 2-5, 2026, which is expected to attract significant attention from customers, partners, and investors, thereby enhancing brand visibility.
- Wireless Edge Technology: The company will discuss how advancing wireless edge technology supports mission-critical connectivity, cloud access, and emerging AI-driven applications, demonstrating its technological leadership in global deployments and strengthening its competitive position in the market.
- Product Demonstrations: Inseego will present commercially available devices and solutions powered by the latest 5G-Advanced technology, aimed at meeting a broad range of consumer, enterprise, and service provider needs, thereby reinforcing its leadership in high-performance 5G hardware and cloud software services.
- SaaS Platform Highlights: The company will highlight its Inseego Subscribe cloud-based SaaS platform, which enables service providers to manage the subscriber lifecycle, further simplifying wireless deployments and network operations while enhancing customer satisfaction and market share.
See More
Inseego and AT&T Launch 5G Fixed Wireless Solution for Businesses
- New Device Collaboration: Inseego partners with AT&T Business to launch the Wavemaker FX4200, designed to simplify the complexity of enterprise wireless networks, enabling rapid deployment to meet diverse business needs.
- High-Performance Connectivity: The FX4200 supports up to 256 Wi-Fi connections and is 5G and LTE compatible, providing enterprise-grade security and reliability, allowing businesses to operate efficiently without on-site IT support.
- Intelligent Management Features: The device integrates remote device management and real-time performance monitoring, enabling businesses to easily manage multiple locations, enhancing operational efficiency and reducing management costs.
- Market Availability: The Wavemaker FX4200 is now available through AT&T Business, paired with AT&T Internet Air® services, providing a robust fixed wireless connectivity solution that further strengthens AT&T's 5G product portfolio.
See More
Inseego Corp. Announces Q4 2025 Financial Results Release Date
- Earnings Release Schedule: Inseego Corp. will release its Q4 2025 financial results on February 19, 2026, after market close, providing investors with crucial financial data and business outlook.
- Conference Call Timing: The company will host a conference call on the same day at 5:00 PM ET (2:00 PM PT) to discuss its financial results and future outlook, enhancing engagement with investors.
- Webcast Availability: The call will be accessible via a live audio webcast from the 'Investor Relations' section of the company's website, ensuring global investors can receive real-time information and improve transparency.
- Replay Service: An audio replay of the conference call will be available for two weeks post-call, allowing investors who could not attend live to access important information, further strengthening communication between the company and its investors.
See More
Inseego Corp. Completes $26M Repurchase of $42M Preferred Stock
- Preferred Stock Buyback: Inseego has completed the repurchase of all $42 million in preferred stock for a total consideration of $26 million, achieving a 38% discount, which will significantly alleviate the company's long-term financial obligations.
- Cash Payment Structure: The repurchase amount will be paid in three installments, with the first payment made at closing, and the subsequent payments due six and twelve months later, thereby optimizing the company's cash flow management.
- Capital Structure Improvement: By fully retiring the preferred stock, CFO Steven Gatoff stated that this move will further enhance the company's balance sheet and increase shareholder value, reflecting the ongoing effort to simplify the capital structure.
- Strengthened Shareholder Relations: This transaction allows Mubadala Capital, previously a preferred stockholder, to become a minority shareholder in common stock, with CEO Juho Sarvikas emphasizing the importance of this long-term partnership in driving the company's sustained growth.
See More
insitro to Present AI Drug Discovery Updates at J.P. Morgan Healthcare Conference
- Company Update: Daphne Koller, Ph.D., founder and CEO of insitro, will present an update on the company's AI-enabled drug discovery engine and therapeutic candidates advancing to the clinic at the J.P. Morgan Healthcare Conference on January 12, showcasing ongoing innovation in cutting-edge medical technology.
- Technology Platform: insitro's AI platform, built on causal biology, integrates human and cellular data to reveal disease onset and progression through machine learning, aiming to treat metabolic diseases and neuroscience disorders at their root, highlighting its potential in precision medicine.
- Funding Support: The company has raised approximately $800 million in capital, including around $150 million from non-dilutive pharma partnerships, indicating strong financing capabilities and market trust within the industry.
- Industry Impact: insitro's innovative approach not only enhances drug development efficiency but also has the potential to transform traditional treatment methods, improving patient outcomes and further solidifying its competitive position in the biopharmaceutical sector.
See More
insitro Launches CellPaint-POSH Platform, Enhancing Gene Function Mapping Capabilities
- Technological Innovation: insitro's CellPaint-POSH platform integrates CRISPR screening and high-content imaging to enable scalable mapping of gene functions, showcasing the complexity of biological networks and advancing the depth and breadth of drug discovery.
- Data Interpretation Capability: The platform employs self-supervised machine learning to extract subtle biological relationships from raw pixel data, identifying 2.5 times more functional gene relationships than conventional analyses, significantly enhancing therapeutic target discovery efficiency.
- Industry Transformation: By providing a high-resolution map of disease biology, the CellPaint-POSH platform revolutionizes traditional target identification methods, allowing researchers to comprehensively understand cellular complexity without relying on predefined metrics.
- Funding Support: insitro has raised approximately $800 million in funding, including $150 million from non-dilutive pharmaceutical partnerships, reflecting strong market confidence in its innovative platform.
See More
Inseego to Showcase 5G Solutions at MWC 2026
- Participation in MWC 2026: Inseego will showcase its 5G mobile broadband and fixed wireless access solutions at the Mobile World Congress in Barcelona from March 2-5, 2026, which is expected to attract significant attention from customers, partners, and investors, thereby enhancing brand visibility.
- Wireless Edge Technology: The company will discuss how advancing wireless edge technology supports mission-critical connectivity, cloud access, and emerging AI-driven applications, demonstrating its technological leadership in global deployments and strengthening its competitive position in the market.
- Product Demonstrations: Inseego will present commercially available devices and solutions powered by the latest 5G-Advanced technology, aimed at meeting a broad range of consumer, enterprise, and service provider needs, thereby reinforcing its leadership in high-performance 5G hardware and cloud software services.
- SaaS Platform Highlights: The company will highlight its Inseego Subscribe cloud-based SaaS platform, which enables service providers to manage the subscriber lifecycle, further simplifying wireless deployments and network operations while enhancing customer satisfaction and market share.
See More
Inseego and AT&T Launch 5G Fixed Wireless Solution for Businesses
- New Device Collaboration: Inseego partners with AT&T Business to launch the Wavemaker FX4200, designed to simplify the complexity of enterprise wireless networks, enabling rapid deployment to meet diverse business needs.
- High-Performance Connectivity: The FX4200 supports up to 256 Wi-Fi connections and is 5G and LTE compatible, providing enterprise-grade security and reliability, allowing businesses to operate efficiently without on-site IT support.
- Intelligent Management Features: The device integrates remote device management and real-time performance monitoring, enabling businesses to easily manage multiple locations, enhancing operational efficiency and reducing management costs.
- Market Availability: The Wavemaker FX4200 is now available through AT&T Business, paired with AT&T Internet Air® services, providing a robust fixed wireless connectivity solution that further strengthens AT&T's 5G product portfolio.
See More
Inseego Corp. Announces Q4 2025 Financial Results Release Date
- Earnings Release Schedule: Inseego Corp. will release its Q4 2025 financial results on February 19, 2026, after market close, providing investors with crucial financial data and business outlook.
- Conference Call Timing: The company will host a conference call on the same day at 5:00 PM ET (2:00 PM PT) to discuss its financial results and future outlook, enhancing engagement with investors.
- Webcast Availability: The call will be accessible via a live audio webcast from the 'Investor Relations' section of the company's website, ensuring global investors can receive real-time information and improve transparency.
- Replay Service: An audio replay of the conference call will be available for two weeks post-call, allowing investors who could not attend live to access important information, further strengthening communication between the company and its investors.
See More
Inseego Corp. Completes $26M Repurchase of $42M Preferred Stock
- Preferred Stock Buyback: Inseego has completed the repurchase of all $42 million in preferred stock for a total consideration of $26 million, achieving a 38% discount, which will significantly alleviate the company's long-term financial obligations.
- Cash Payment Structure: The repurchase amount will be paid in three installments, with the first payment made at closing, and the subsequent payments due six and twelve months later, thereby optimizing the company's cash flow management.
- Capital Structure Improvement: By fully retiring the preferred stock, CFO Steven Gatoff stated that this move will further enhance the company's balance sheet and increase shareholder value, reflecting the ongoing effort to simplify the capital structure.
- Strengthened Shareholder Relations: This transaction allows Mubadala Capital, previously a preferred stockholder, to become a minority shareholder in common stock, with CEO Juho Sarvikas emphasizing the importance of this long-term partnership in driving the company's sustained growth.
See More
insitro to Present AI Drug Discovery Updates at J.P. Morgan Healthcare Conference
- Company Update: Daphne Koller, Ph.D., founder and CEO of insitro, will present an update on the company's AI-enabled drug discovery engine and therapeutic candidates advancing to the clinic at the J.P. Morgan Healthcare Conference on January 12, showcasing ongoing innovation in cutting-edge medical technology.
- Technology Platform: insitro's AI platform, built on causal biology, integrates human and cellular data to reveal disease onset and progression through machine learning, aiming to treat metabolic diseases and neuroscience disorders at their root, highlighting its potential in precision medicine.
- Funding Support: The company has raised approximately $800 million in capital, including around $150 million from non-dilutive pharma partnerships, indicating strong financing capabilities and market trust within the industry.
- Industry Impact: insitro's innovative approach not only enhances drug development efficiency but also has the potential to transform traditional treatment methods, improving patient outcomes and further solidifying its competitive position in the biopharmaceutical sector.
See More
insitro Launches CellPaint-POSH Platform, Enhancing Gene Function Mapping Capabilities
- Technological Innovation: insitro's CellPaint-POSH platform integrates CRISPR screening and high-content imaging to enable scalable mapping of gene functions, showcasing the complexity of biological networks and advancing the depth and breadth of drug discovery.
- Data Interpretation Capability: The platform employs self-supervised machine learning to extract subtle biological relationships from raw pixel data, identifying 2.5 times more functional gene relationships than conventional analyses, significantly enhancing therapeutic target discovery efficiency.
- Industry Transformation: By providing a high-resolution map of disease biology, the CellPaint-POSH platform revolutionizes traditional target identification methods, allowing researchers to comprehensively understand cellular complexity without relying on predefined metrics.
- Funding Support: insitro has raised approximately $800 million in funding, including $150 million from non-dilutive pharmaceutical partnerships, reflecting strong market confidence in its innovative platform.
See More
